Clinical Trials Directory

Trials / Unknown

UnknownNCT02996838

A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics

Phase I Study of Tolerance and Pharmacokinetics of TQ-B3234 in Patients With Advanced Cancer

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

To study the pharmacokinetic characteristics of TQ-B3234 in the human body, recommend a reasonable regimen for subsequent research.

Conditions

Interventions

TypeNameDescription
DRUGTQ-B3234TQ-B3234 p.o. qd

Timeline

Start date
2017-05-11
Primary completion
2020-12-01
Completion
2020-12-01
First posted
2016-12-19
Last updated
2019-05-21

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02996838. Inclusion in this directory is not an endorsement.

A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics (NCT02996838) · Clinical Trials Directory